Antibody-Drug Conjugates | Special Topics | Trends and Market Dynamics – Multi-indication | G7 | 2023

Antibody-drug conjugates have proven to be a versatile and effective tool in treating a wide range of tumor types, establishing the drug class as a valuable weapon against cancer. The approval of agents targeting various extracellular antigens associated with tumorigenesis continues to transform the treatment paradigm for a plethora of oncology indications. The late-phase pipeline is particularly active and promising. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates in select oncology indications and analyzes key market trends and dynamics.

QUESTIONS ANSWERED

• What is the current landscape for approved antibody-drug conjugates? What are their approval timelines?
• What is the market positioning of emerging antibody-drug conjugates?
• How will the indication-specific market trends and dynamics evolve?
• What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, and geography? How will the market evolve over the 2022-2032 forecast period?

GEOGRAPHIES

United States, EU5, Japan.

EPIDEMIOLOGY

Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.

FORECAST

10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.

KEY DRUGS COVERED

Select approved therapies (e.g., Enhertu, Kadcyla, Trodelvy, Polivy) and select emerging therapies expected to gain approval.

EMERGING THERAPIES

Agents in Phase 3 development.

PRODUCT DESCRIPTION

Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.